Success Story: From Sri Lanka to NIW Approval for a Molecular Biology Researcher without RFE
Client’s Testimonial:
"Thank you for all your assistance. I really appreciate it."
On April 25th, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a Postdoctoral Researcher in the Field of Molecular Biology (Approval Notice).
General Field: Molecular Biology
Position at the Time of Case Filing: Postdoctoral Researcher
Country of Origin: Sri Lanka
State of Residence at the Time of Filing: Hawaii
Approval Notice Date: April 25th, 2026
Processing Time: 2 months, 19 days
Case Summary:
This NIW approval highlights a postdoctoral researcher from Sri Lanka whose work bridges molecular diagnostics, immunology, and translational cancer biology to advance disease detection and therapeutic development. The proposed endeavor focuses on developing advanced disease detection and therapeutic validation models using integrative molecular and translational biology approaches, including laboratory disease models, gene editing, immunological assays, and multi-omic analyses, to identify and validate novel therapeutic targets that regulate inflammation, autoimmunity, and cancer. At the time of filing, the client was continuing this work in the United States through a postdoctoral research appointment aligned with the proposed endeavor.
Research with National Importance
In the petition, we demonstrated substantial merit and national importance by linking the client's endeavor to U.S. needs in earlier and more accurate diagnosis of inflammation-driven diseases, where delayed detection directly worsens patient outcomes and drives up healthcare costs. We emphasized that autoimmune conditions like rheumatoid arthritis and inflammatory bowel disease remain chronically underdiagnosed, and that the client's molecular detection models address a concrete gap in the diagnostic pipeline, one with measurable downstream impact on treatment access and disease progression. We also connected the client's cancer-focused research to the burden of inflammatory breast cancer and triple-negative breast cancer, two of the most clinically aggressive and treatment-resistant malignancies, where the absence of validated therapeutic targets remains a key barrier to improving survival rates.
Academic Contributions and Recognition
The petition documented a strong record of scholarly output and peer trust. The client's work includes 3 peer-reviewed journal articles (1 of them first-authored) and 2 first-authored conference abstracts, published in highly ranked journals in the field. The body of work has received 70 citations, reflecting meaningful reliance by researchers across biosensors, microbiology, and molecular immunology, evidence of interdisciplinary reach. The petition also highlighted at least 2 completed peer reviews for respected journals in the field, further confirming recognition of the client's expertise by the academic community. Additionally, the client's research has been supported by funding from the National Institutes of Health, an institution that reserves grants exclusively for research advancing national health priorities, including cancer research and expanding knowledge of living systems to improve public health.
NIW Approval and Outlook
The I-140 NIW petition was filed and approved in over 2 months without RFE. In the filing, we showed that the proposed endeavor has substantial merit and national importance, that the client is well-positioned to advance it through a strong publication, citation, peer-recognition, and funding record, and that granting the waiver benefits the United States by enabling continued progress in developing advanced molecular tools for cancer detection and inflammatory disease therapeutics. We are honored to have supported this outstanding researcher and extend our sincere congratulations and warmest best wishes for continued success in advancing science that benefits patients and the nation.